Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.49 |
| ▸ | TTR | P02766 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.49 |
| ▸ | CBR1 | P16152 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14157279 | 0.89 | TTR (0.61) | SLC22A12TTRHPGDNR1I2LMNA | |
| SCHEMBL30335212 | 0.83 | AR (0.46) | SLC22A12PGR | |
| SCHEMBL5606502 | 0.83 | AR (0.46) | SLC22A12PGR | |
| SCHEMBL29574172 | 0.82 | TTR (0.56) | SLC22A12TTRHPGDNR1I2LMNA | |
| SCHEMBL5142953 | 0.81 | SLC22A12 (0.41) | SLC22A12TTRHPGDNR1I2LMNA | |
| SCHEMBL11372623 | 0.74 | AR (0.47) | SLC22A12HPGDMAPTKDM4EMEN1 | |
| SCHEMBL11182601 | 0.73 | AR (0.46) | SLC22A12TTRHPGDNR1I2LMNA | |
| SCHEMBL28688126 | 0.73 | KDM4E (0.59) | SLC22A12HPGDLMNAMAPTSLC6A2 | |
| SCHEMBL2525720 | 0.73 | CA3 (0.50) | PGR | |
| SCHEMBL10540653 | 0.73 | TTR (0.83) | TTRHPGDNR1I2LMNAPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054884-A1 | 4-SUBSTITUTED 2-ARYLOXYPHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2007027878-A2 | 4-SUBSTITUTED 2-ARYLOXYPHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054884-A1 | 4-SUBSTITUTED 2-ARYLOXYPHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | CLPP, TYR, MRPL21 | SLC22A12 2044/4885TTR 2906/4885HPGD 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.